GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial

• Main Authors: Dan Dan Tian (Author), Samuel K. Bennett (Author), Lucy A. Coupland (Author), Kathryn Forwood (Author), Yadanar Lwin (Author), Niloofar Pooryousef (Author), Illa Tea (Author), Thy T. Truong (Author), Teresa Neeman (Author), Philip Crispin (Author), James D'Rozario (Author), Anneke C. Blackburn (Author)
• Format: Book
• Published: Wiley, 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Dichloroacetate (DCA) is an investigational drug targeting the glycolytic hallmark of cancer by inhibiting pyruvate dehydrogenase kinases (PDK). It is metabolized by GSTZ1, which has common polymorphisms altering enzyme or promoter activity. GSTZ1 is also irreversibly inactivated by DCA. In...